Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: One institution experience

Abstract

Background: Triple-negative breast carcinoma (TNBC) patients do not benefit from hormone-or human epidermal growth factor receptor 2-(HER2-) targeted therapies. Accurate testing is pivotal for these patients. Methods: TNBC cases that were retested at our institution during a 3-year period were evaluated for concordance rates in estrogen (ER) and progesterone (PR) receptor and HER2 results. Results: We found 19 (22%) discrepancies (13 major/6 minor) among 86 cases. Minor discrepancies were in HER2 changes by immunohistochemistry, and all cases were demonstrated to be negative by and dual in situ hybridization. All major discrepancies were in ER/PR expression changes. In only 2 cases the treatment changed based on repeated results and/or patient history. Conclusions: Discrepancies in prognostic/predictive testing continue to be frequent despite rigorous regulations. However, since for the majority of patients in our setting, the treatment plan did not change, reflex retesting for TNBC has been deemed unnecessary in our institution.